Brandon Weckbaugh, M.D. - Stormont Vail ...

Dr. Brandon R. Weckbaugh

Claim this profile

Cotton O'Neil Cancer Center / Stormont Vail Health

Studies Non-Small Cell Lung Cancer
Studies Acute Myeloid Leukemia
7 reported clinical trials
17 drugs studied

Area of expertise

1

Non-Small Cell Lung Cancer

Brandon R. Weckbaugh has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I
2

Acute Myeloid Leukemia

Brandon R. Weckbaugh has run 2 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

FLT3 positive
D835 positive
RUNX1-RUNX1T1 negative

Affiliated Hospitals

Image of trial facility.

Cotton O'Neil Cancer Center / Stormont Vail Health

Clinical Trials Brandon R. Weckbaugh is currently running

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Recruiting

1 award

Phase 2

7 criteria

Image of trial facility.

Screening Tool

for Myeloid Cancer

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Recruiting

0 awards

Phase 2

1 criteria

More about Brandon R. Weckbaugh

Clinical Trial Related

1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Brandon R. Weckbaugh has experience with

  • Biospecimen Collection
  • Venetoclax
  • Azacitidine
  • Text-Based Cessation Intervention
  • Cabozantinib S-malate
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Brandon R. Weckbaugh specialize in?

Is Brandon R. Weckbaugh currently recruiting for clinical trials?

Are there any treatments that Brandon R. Weckbaugh has studied deeply?

What is the best way to schedule an appointment with Brandon R. Weckbaugh?

What is the office address of Brandon R. Weckbaugh?

Is there any support for travel costs?